Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Wanbury's full-year profit jumps 117% on better mix and procurement savings

Net profit surged to ₹66.1 crore for FY26, though a West Asia-related export disruption dented the final quarter.


Mkt cap₹895 cr
P/E20.83×
ROE51.51%
Debt / eq.2.92
₹66.1 cr FY26 net profit, up 117% year-on-year.

What's new

  • FY26 net profit jumped 117% to ₹66.1 crore on 8.5% higher revenue of ₹650.3 crore.
  • Q4 revenue fell 4.3% to ₹164.6 crore due to API export disruptions from the West Asia crisis.
  • Commercial launch of a new anaesthetic API from the Tanuku facility.

Why this matters

The annual profit surge confirms the payoff from Wanbury's product-mix and efficiency work. The Q4 revenue dip, however, is a direct hit from a geopolitical event, showing the export business remains exposed to logistics shocks outside management's control. The new API and a clean South Korean inspection are steps toward de-risking that exposure.

What we're watching

  • Q1 FY27 export dispatch normalisation after the March disruption.
  • Sales trajectory of the newly launched anaesthetic API.
  • Whether the procurement and mix efficiencies hold as revenue scales.

The full read

Wanbury's full-year results show a stark contrast between profitability and top-line momentum. Net profit surged 117% to ₹66.1 crore as a better product mix and procurement efficiencies flowed straight to the bottom line. Revenue grew a more modest 8.5% to ₹650.3 crore. The disconnect sharpened in the final quarter: revenue slipped 4.3% to ₹164.6 crore after a March conflict in West Asia disrupted API export schedules. A ₹3.6 crore one-time charge couldn't stop quarterly profit from rising 7.2% to ₹21.7 crore. Beyond the financials, the company launched a new anaesthetic API from Tanuku and cleared a zero-observation inspection from South Korea's MFDS. The annual story is clear: margins improved. The quarterly story is a warning: the export channel is fragile.

Questions answered

How did Wanbury drive a 117% profit increase on just 8.5% revenue growth?
The company cited a better product mix, higher yields, and procurement efficiencies. These factors more than doubled EPS to ₹20.55, amplifying the profit impact of the moderate revenue gain.
Why did the fourth quarter revenue decline?
Q4 revenue fell 4.3% to ₹164.6 crore due to disruptions to API export dispatches caused by the West Asia crisis in March. The company characterized it as a timing issue.
What was the one-time charge in Q4?
Wanbury took a ₹3.6 crore one-time charge in the fourth quarter. Despite this hit, quarterly profit after tax still rose 7.2% to ₹21.7 crore.
What are the key operational updates?
Wanbury commercially launched a new anaesthetic API from its Tanuku facility and received a zero-observation inspection outcome from South Korea's MFDS, clearing a regulatory hurdle.
Mentioned: ₹66.1 cr FY26 PAT · ₹164.6 cr Q4 revenue · Tanuku facility
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.